ClinicalTrials.gg
CompletedNCT03292016Updated Aug 13, 2020Results posted

A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes

A Phase 2 interventional study of APL-130277 and APO-go in Parkinson Disease, sponsored by Sumitomo Pharma America, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-13.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 32 studies testing apomorphine in Parkinson Disease — 1 open to participants now, 2 under way, 1 of them phase 3. Apomorphine · Parkinson Disease.

Enrollment
30th of 32
8 · median 42
Started
2017
with 4 others
Phase 2
10 of 32
none open now
Registered
27th of 32
by date
Lead sponsor
6 of 32
Sumitomo Pharma America, Inc.

Among the 32 studies testing apomorphine in Parkinson Disease, this one is the 30th largest by enrollment, is one of 5 that started in 2017, is one of 10 in phase 2, and was the 27th registered.

Parkinson Disease

4,581 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 32 studies testing apomorphine in Parkinson Disease is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About apomorphine

Apomorphine: first FDA approval 2004 (APOKYN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 313 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing apomorphine in Parkinson Disease, or all of them as a file.
02

Study summary

A study that compares the extent to which apomorphine becomes available in the body after taking either an investigational drug containing apomorphine or apomorphine that is injected under the skin in people with PD complicated by "OFF" episodes.

Read the detailed description

This multi-center study will aim to evaluate the pharmacokinetics (PK) and comparative bioavailability of a single dose of APL-130277 sublingual thin film with subcutaneous (s.c.) APO-go® and s.c. APOKYN® in subjects with Parkinson's disease (PD). The dose of APOKYN® (≤ 5 mg) will be based on the subjects' current prescribed dose. The study is designed as an open-label, randomized, three-way crossover. Subjects will receive all three treatment arms with a minimum 1-day wash-out between each visit (excluding the screening visit) and will be randomly assigned to one of the six sequences

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Off Episodes
  • Parkinson Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥ 18 years of age.
  2. Clinical diagnosis of Idiopathic PD, consistent with UK Brain Bank Criteria (excluding the "more than one affected relative" criterion).
  3. response to Levodopa (L-Dopa) with well-defined "OFF" episodes, as determined by the Investigator.
  4. Receiving APOKYN® of ≤ 5 mg per dose for at least 4 weeks before the Screening Visit.
  5. Receiving stable doses of L-Dopa/carbidopa (immediate or sustained release) administered at least 4 times per day OR Rytary™ administered 3 times per day, for at least 4 weeks before the Screening Visit. Adjunctive PD medication regimens must be maintained at a stable dose for at least 4 weeks prior to the Screening Visit with the exception that MAOB inhibitors must be maintained at a stable level for at least 8 weeks prior to the Screening Visit.
  6. No planned medication change(s) or surgical intervention anticipated during the course of study.
  7. Patients must experience a well-defined "OFF" episode in the morning if they do not take their morning PD medications on schedule, and must be willing to delay morning doses on the 3 study dosing days
  8. Stage III or less on the modified Hoehn and Yahr scale in the "ON" state.
  9. (MMSE) score > 23.
  10. If female and of , must agree to use one of the following methods of :

    • Oral contraceptive;
    • Contraceptive patch;
    • Barrier (diaphragm, sponge or condom) plus spermicidal preparations;
    • Intrauterine contraceptive system;
    • Levonorgestrel implant;
    • Medroxyprogesterone acetate contraceptive injection;
    • Complete abstinence from sexual intercourse;
    • Hormonal vaginal contraceptive ring; or
    • Surgical sterilization or partner sterile (must have documented proof).
  11. Male patients must be either surgically sterile, agree to be sexually abstinent or use a barrier method of birth control (e.g., condom) or maintain a monogamous relationship with a person who is not of child-bearing potential from first study drug administration until 30days after final drug administration.
  12. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study-related procedures to complete the study.
  13. Able to understand the consent form, and to provide written

Exclusion criteria

Exclusion Criteria:

  1. Atypical or secondary parkinsonism.
  2. Previous treatment with any of the following: continuous subcutaneous (s.c.) apomorphine infusion; or Duodopa/Duopa.
  3. to APO-go® or APOKYN® or to apomorphine hydrochloride or any marcrolide antibiotic or any of the ingredients APO-go® or APOKYN® (notably sodium metabisulfite).
  4. Female who is pregnant or lactating.
  5. Participation in a clinical trial within 30 days prior to the Screening Visit.
  6. Receipt of any (ie, unapproved) medication within 30 days prior to the Screening Visit.
  7. Any selective 5HT3 antagonists (ie, ondansetron, granisetron, dolasetron, palonosetron, alosetron), dopamine antagonists (excluding quetiapine and clozapine) or dopamine depleting agents within 30 days prior to the Screening Visit.
  8. Drug or alcohol dependency in the past 12 months.
  9. History of malignant melanoma.
  10. medical, surgical, or laboratory abnormality in the opinion of the Investigator.
  11. Major psychiatric disorder including, but not limited to, dementia, bipolar disorder, psychosis, or any disorder that, in the opinion of the Investigator, requires ongoing treatment that would make study participation unsafe or make treatment compliance difficult.
  12. History of clinically significant hallucinations during the past 6 months.
  13. History of clinically significant impulse control disorder(s).
  14. Dementia that precludes providing or would interfere with participation in the study.
  15. Current suicidal ideation within one year prior to the Screening Visit as evidenced by answering "yes" to Questions 4 or 5 on the suicidal ideation portion of the Columbia-Suicide Severity Rating Scale (C-SSRS) or attempted suicide within the last 5 years.
  16. Donation of blood plasma in the 30 days prior to first dosing.
  17. Cankers or mouth sores within 30 days prior to the Screening Visit, or other clinically significant oral pathology in the opinion of the Investigator. The Investigator should follow-up with an appropriate specialist on any finding, if indicated, before enrolling a patient into the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    APL-130277, sublingual thin film

    APL-130277, sublingual thin film, once daily

    Drug: APL-130277

  • Active comparator
    Subcutaneous APO-go

    Subcutaneous APO-go, once daily

    Drug: APO-go

  • Active comparator
    Subcutaneous APOKYN

    Subcutaneous APOKYN, once daily

    Drug: Apokyn

Interventions

  • APL-130277 sublingual thin film

    Also known as: amomorphine

  • DrugAPO-go

    Subcutaneous APO-go

    Also known as: amomorphine

  • DrugApokyn

    Subcutaneous APOKYN

    Also known as: amomorphine

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Dose normalized maximum observed plasma concentration (Cmax)

    Time frame: Day 1

  2. Observed Time of the Maximum Concentration (Tmax)

    Time from dosing to Cmax, observed by inspection of individual subject plots of plasma concentration versus time.

    Time frame: Day 1

  3. Area Under the Concentration- Time Curve (AUC Last)

    area under the concentration-time curve from time zero to the last measurable plasma concentration-time curve using the linear up log down trapezoidal rule.

    Time frame: Day 1

  4. Area Under the Concentration- Time Curve (AUC Inf)

    area under the concentration-time curve from time zero extrapolated to infinity using the linear up log down trapezoidal rule.

    Time frame: Day 1

  5. Mean Residence Time (MRT)

    Mean residence time during one dosing interval calculated using the following equation: MRT = AUMCinf/AUC inf. AUMCinf is the area under the first moment (time.plasma concentration vs. time) curve.

    Time frame: Day 1

  6. Metabolite/Parent (M/P) Drug Concentration Ratio -Cmax

    Metabolite (apomorphine sulfate) to Parent exposure ratio, Cmax, corrected for molecular weight differences.

    Time frame: Day 1

  7. Apparent Total Clearance of the Drug From Plasma After Oral Administration (CL/F)

    Apparent total clearance of the drug from plasma extravascular administration, calculated as Dose/AUCinf.

    Time frame: Day 1

  8. Apparent Volume of Distribution After Non-intravenous Administration (V/F)

    Apparent volume of distribution after extravascular administration, calculated as Dose/(AUCinf \* λz).

    Time frame: Day 1

  9. Terminal-phase Half-life (t½)

    Terminal phase half-life, as calculated by the following equation: t½ = ln(2)/λz.

    Time frame: Day 1

  10. Terminal-phase Rate Constant ( λz)

    Apparent terminal elimination rate constant, determined by log linear regression of the plasma concentration versus time data that was judged to be in the log-linear elimination phase. At least 3 data points in the terminal phase will be used in the determination of the rate constant.

    Time frame: Day 1

  11. Metabolite/Parent (M/P) Drug Concentration Ratio -AUC Last

    Metabolite (apomorphine sulfate) to Parent exposure ratio, AUClast, corrected for molecular weight differences.

    Time frame: Day 1

07

Results

Posted Aug 13, 2020

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneAPL-130277, Then APOKYN, Then APO-goAPL-130277, Then APO-go, Then APOKYNAPOKYN, Then APL-130277, Then APO-goAPOKYN, Then APO-go, Then APL-130277APO-go, Then APL-130277, Then APOKYNAPO-go, Then APOKYN, Then APL-130277
Started112112
Completed112112
Not completed000000
First Washout
Participant flow — First Washout
MilestoneAPL-130277, Then APOKYN, Then APO-goAPL-130277, Then APO-go, Then APOKYNAPOKYN, Then APL-130277, Then APO-goAPOKYN, Then APO-go, Then APL-130277APO-go, Then APL-130277, Then APOKYNAPO-go, Then APOKYN, Then APL-130277
Started112112
Completed112112
Not completed000000
Second Intervention
Participant flow — Second Intervention
MilestoneAPL-130277, Then APOKYN, Then APO-goAPL-130277, Then APO-go, Then APOKYNAPOKYN, Then APL-130277, Then APO-goAPOKYN, Then APO-go, Then APL-130277APO-go, Then APL-130277, Then APOKYNAPO-go, Then APOKYN, Then APL-130277
Started112112
Completed112112
Not completed000000
Second Washout
Participant flow — Second Washout
MilestoneAPL-130277, Then APOKYN, Then APO-goAPL-130277, Then APO-go, Then APOKYNAPOKYN, Then APL-130277, Then APO-goAPOKYN, Then APO-go, Then APL-130277APO-go, Then APL-130277, Then APOKYNAPO-go, Then APOKYN, Then APL-130277
Started112112
Completed102112
Not completed010000
Withdrew: Adverse event010000
Third Intervention
Participant flow — Third Intervention
MilestoneAPL-130277, Then APOKYN, Then APO-goAPL-130277, Then APO-go, Then APOKYNAPOKYN, Then APL-130277, Then APO-goAPOKYN, Then APO-go, Then APL-130277APO-go, Then APL-130277, Then APOKYNAPO-go, Then APOKYN, Then APL-130277
Started102112
Completed102112
Not completed000000

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax)

Dose normalized maximum observed plasma concentration (Cmax)

Time frame:
Day 1
Reported as:
Geometric least squares mean · (ng/mL)/(mg)
Maximum Observed Plasma Concentration (Cmax)
(ng/mL)/(mg)APL-130277, Sublingual Thin FilmSubcutaneous APOKYNSubcutaneous APO-go
Maximum Observed Plasma Concentration (Cmax)0.281 (0.191 to 0.413)2.29 (1.46 to 3.59)2.74 (1.82 to 4.13)
Statistical analysis
  • APL-130277, Sublingual Thin Film vs Subcutaneous APOKYN · Mixed Models Analysis · Geometric mean ratio (apl-130277/apokyn): 12.3 · 90% CI 7.5 to 20.3With fixed effects-treatment and period, random effect-subject nested within sequence to analyze natural-log transformed dose normalized parameter.
  • APL-130277, Sublingual Thin Film vs Subcutaneous APO-go · Geometric mean ratio (apl-130277/apo-go): 10.3 · 90% CI 6.5 to 16.3
  • Subcutaneous APOKYN vs Subcutaneous APO-go · Geometric mean ratio (apokyn/apo-go): 83.4 · 90% CI 50.5 to 137.6
  • APL-130277, Sublingual Thin Film vs Subcutaneous APO-go · Ratio: 0.21The comparative bioavailability calculated as the ratio of the Test/Reference between APL 20 mg and APO-Go 3 mg
  • APL-130277, Sublingual Thin Film vs Subcutaneous APOKYN · Ratio: 0.13The comparative bioavailability calculated as the ratio of the Test/Reference between APL 20 mg and APOKYN 3 mg
  • Subcutaneous APOKYN vs Subcutaneous APO-go · Ratio: 1.16The comparative bioavailability calculated as the ratio of the Test/Reference between APO-Go 3 mg and APOKYN 3 mg
  • APL-130277, Sublingual Thin Film vs Subcutaneous APO-go · Ratio: 0.16The comparative bioavailability calculated as the ratio of the Test/Reference between APL 25 mg and APO-Go 4 mg
  • APL-130277, Sublingual Thin Film vs Subcutaneous APOKYN · Ratio: 0.17The comparative bioavailability calculated as the ratio of the Test/Reference between APL 25 mg and APOKYN 4 mg
  • Subcutaneous APOKYN vs Subcutaneous APO-go · Ratio: 1.12The comparative bioavailability calculated as the ratio of the Test/Reference between APO-Go 4 mg and APOKYN 4 mg
  • APL-130277, Sublingual Thin Film vs Subcutaneous APO-go · Ratio: 0.08The comparative bioavailability calculated as the ratio of the Test/Reference between APL 30 mg and APO-Go 5 mg
  • APL-130277, Sublingual Thin Film vs Subcutaneous APOKYN · Ratio: 0.09The comparative bioavailability calculated as the ratio of the Test/Reference between APL 30 mg and APOKYN 5 mg
  • Subcutaneous APOKYN vs Subcutaneous APO-go · Ratio: 1.04The comparative bioavailability calculated as the ratio of the Test/Reference between APO-Go 5 mg and APOKYN 5 mg
PrimaryObserved Time of the Maximum Concentration (Tmax)

Time from dosing to Cmax, observed by inspection of individual subject plots of plasma concentration versus time.

Time frame:
Day 1
Reported as:
Median · hour
Observed Time of the Maximum Concentration (Tmax)
hourAPL-130277, Sublingual Thin FilmSubcutaneous APOKYNSubcutaneous APO-go
APL 20 mg, APOKYN 3 mg, and APO-go 3 mg0.75 (0.52 to 0.75)0.38 (0.25 to 0.50)0.38 (0.25 to 0.50)
APL 25 mg, APOKYN 4 mg, and APO-go 4 mg0.63 (0.25 to 1.02)0.25 (0.25 to 0.25)0.26 (0.25 to 0.27)
APL 30 mg, APOKYN 5 mg, and APO-go 5 mg0.75 (0.50 to 1.00)0.38 (0.25 to 0.50)0.25 (0.25 to 0.50)
Statistical analysis
  • APL-130277, Sublingual Thin Film vs Subcutaneous APOKYN · Sign test · p = 0.0625
  • APL-130277, Sublingual Thin Film vs Subcutaneous APO-go · Sign test · p = 0.0313
  • Subcutaneous APOKYN vs Subcutaneous APO-go · Sign test · p = >0.9999
PrimaryArea Under the Concentration- Time Curve (AUC Last)

area under the concentration-time curve from time zero to the last measurable plasma concentration-time curve using the linear up log down trapezoidal rule.

Time frame:
Day 1
Reported as:
Geometric least squares mean · (hxng/mL)/(mg)
Area Under the Concentration- Time Curve (AUC Last)
(hxng/mL)/(mg)APL-130277, Sublingual Thin FilmSubcutaneous APOKYNSubcutaneous APO-go
Area Under the Concentration- Time Curve (AUC Last)0.500 (0.344 to 0.726)2.91 (1.97 to 4.30)3.00 (2.05 to 4.39)
Statistical analysis
  • APL-130277, Sublingual Thin Film vs Subcutaneous APOKYN · Mixed Models Analysis · Geometric mean ratio (apl-130277/apokyn): 17.2 · 90% CI 13.1 to 22.5With fixed effects-treatment and period, random effect-subject nested within sequence to analyze natural-log transformed dose normalized parameter.
  • APL-130277, Sublingual Thin Film vs Subcutaneous APO-go · Mixed Models Analysis · Geometric mean ratio (apl-130277/apokyn): 16.7 · 90% CI 13.0 to 21.3
  • Subcutaneous APOKYN vs Subcutaneous APO-go · Geometric mean ratio (apokyn/apo-go): 96.9 · 90% CI 74.2 to 126.4
  • APL-130277, Sublingual Thin Film vs Subcutaneous APO-go · Ratio: 0.32The comparative bioavailability calculated as the ratio of the Test/Reference between APL 20 mg and APO-Go 3 mg
  • APL-130277, Sublingual Thin Film vs Subcutaneous APOKYN · Ratio: 0.16The comparative bioavailability calculated as the ratio of the Test/Reference between APL 20 mg and APOKYN 3 mg
  • Subcutaneous APOKYN vs Subcutaneous APO-go · Ratio: 1.09The comparative bioavailability calculated as the ratio of the Test/Reference between APO-Go 3 mg and APOKYN 3 mg
  • APL-130277, Sublingual Thin Film vs Subcutaneous APO-go · Ratio: 0.23The comparative bioavailability calculated as the ratio of the Test/Reference between APL 25 mg and APO-Go 4 mg
  • APL-130277, Sublingual Thin Film vs Subcutaneous APOKYN · Ratio: 0.23The comparative bioavailability calculated as the ratio of the Test/Reference between APL 25 mg and APOKYN 4 mg
  • Subcutaneous APOKYN vs Subcutaneous APO-go · Ratio: 1.00The comparative bioavailability calculated as the ratio of the Test/Reference between APO-Go 4 mg and APOKYN 4 mg
  • APL-130277, Sublingual Thin Film vs Subcutaneous APO-go · Ratio: 0.15The comparative bioavailability calculated as the ratio of the Test/Reference between APL 30 mg and APO-Go 5 mg
  • APL-130277, Sublingual Thin Film vs Subcutaneous APOKYN · Ratio: 0.14The comparative bioavailability calculated as the ratio of the Test/Reference between APL 30 mg and APOKYN 5 mg
  • Subcutaneous APOKYN vs Subcutaneous APO-go · Ratio: 0.96The comparative bioavailability calculated as the ratio of the Test/Reference between APO-Go 5 mg and APOKYN 5 mg
PrimaryArea Under the Concentration- Time Curve (AUC Inf)

area under the concentration-time curve from time zero extrapolated to infinity using the linear up log down trapezoidal rule.

Time frame:
Day 1
Reported as:
Geometric least squares mean · (hxng/mL)/(mg)
Area Under the Concentration- Time Curve (AUC Inf)
(hxng/mL)/(mg)APL-130277, Sublingual Thin FilmSubcutaneous APOKYNSubcutaneous APO-go
Area Under the Concentration- Time Curve (AUC Inf)0.52 (0.36 to 0.76)2.97 (2.01 to 4.39)3.04 (2.08 to 4.45)
Statistical analysis
  • APL-130277, Sublingual Thin Film vs Subcutaneous APOKYN · Mixed Models Analysis · Geometric mean ratio (apl-130277/apokyn): 17.6 · 90% CI 13.7 to 22.5With fixed effects-treatment and period, random effect-subject nested within sequence to analyze natural-log transformed dose normalized parameter.
  • APL-130277, Sublingual Thin Film vs Subcutaneous APO-go · Mixed Models Analysis · Geometric mean ratio (apl-130277/apo-go): 17.2 · 90% CI 13.7 to 21.6
  • Subcutaneous APOKYN vs Subcutaneous APO-go · Mixed Models Analysis · Geometric mean ratio (apokyn/apo-go): 97.8 · 90% CI 76.6 to 124.8
PrimaryMean Residence Time (MRT)

Mean residence time during one dosing interval calculated using the following equation: MRT = AUMCinf/AUC inf. AUMCinf is the area under the first moment (time.plasma concentration vs. time) curve.

Time frame:
Day 1
Reported as:
Geometric mean · h
Mean Residence Time (MRT)
hAPL-130277, Sublingual Thin FilmSubcutaneous APOKYNSubcutaneous APO-go
APL 20 mg, APOKYN 3 mg, and APO-go 3 mg1.69 ± 5.21.44 ± 4.31.21 ± 19.3
APL 25 mg, APOKYN 4 mg, and APO-go 4 mg1.83 ± 41.51.70 ± 13.81.51 ± 19.0
APL 30 mg, APOKYN 5 mg, and APO-go 5 mg2.15 ± 15.91.23 ± 3.41.08 ± 35.4
PrimaryMetabolite/Parent (M/P) Drug Concentration Ratio -Cmax

Metabolite (apomorphine sulfate) to Parent exposure ratio, Cmax, corrected for molecular weight differences.

Time frame:
Day 1
Reported as:
Geometric mean · no unit
Metabolite/Parent (M/P) Drug Concentration Ratio -Cmax
no unitAPL-130277, Sublingual Thin FilmSubcutaneous APOKYNSubcutaneous APO-go
APL 20 mg, APOKYN 3 mg and APO-go 3 mg61.6 ± 28.815.2 ± 48.911.5 ± 4.0
APL 25 mg, APOKYN 4 mg and APO-go 4 mg32.0 ± 157.19.0 ± 149.37.1 ± 240.3
APL 30 mg, APOKYN 5 mg and APO-go 5 mg61.2 ± 87.013.7 ± 8.211.3 ± 47.6
PrimaryApparent Total Clearance of the Drug From Plasma After Oral Administration (CL/F)

Apparent total clearance of the drug from plasma extravascular administration, calculated as Dose/AUCinf.

Time frame:
Day 1
Reported as:
Geometric mean · L/h
Apparent Total Clearance of the Drug From Plasma After Oral Administration (CL/F)
L/hAPL-130277, Sublingual Thin FilmSubcutaneous APOKYNSubcutaneous APO-go
APL 20 mg, APOKYN 3 mg and APO-go 3 mg2766.9 ± 52.4407.9 ± 33.3375.6 ± 32.2
APL 25 mg, APOKYN 4 mg and APO-go 4 mg1097.8 ± 99.5250.2 ± 140.6253.7 ± 169.6
APL 30 mg, APOKYN 5 mg and APO-go 5 mg1952.1 ± 44.3350.6 ± 4.0299.2 ± 41.0
PrimaryApparent Volume of Distribution After Non-intravenous Administration (V/F)

Apparent volume of distribution after extravascular administration, calculated as Dose/(AUCinf \* λz).

Time frame:
Day 1
Reported as:
Geometric mean · L
Apparent Volume of Distribution After Non-intravenous Administration (V/F)
LAPL-130277, Sublingual Thin FilmSubcutaneous APOKYNSubcutaneous APO-go
APL 20 mg, APOKYN 3 mg and APO-go 3 mg4440.2 ± 72.0577.5 ± 44.3469.3 ± 19.1
APL 25 mg, APOKYN 4 mg and APO-go 4 mg1733.4 ± 52.8420.8 ± 193.7372.2 ± 231.1
APL 30 mg, APOKYN 5 mg and APO-go 5 mg3419.5 ± 67.4452.0 ± 14.7324.2 ± 73.7
PrimaryTerminal-phase Half-life (t½)

Terminal phase half-life, as calculated by the following equation: t½ = ln(2)/λz.

Time frame:
Day 1
Reported as:
Geometric mean · h
Terminal-phase Half-life (t½)
hAPL-130277, Sublingual Thin FilmSubcutaneous APOKYNSubcutaneous APO-go
APL 20 mg, APOKYN 3 mg and APO-go 3 mg1.11 ± 15.60.98 ± 9.90.87 ± 12.6
APL 25 mg, APOKYN 4 mg and APO-go 4 mg1.09 ± 34.31.17 ± 20.61.02 ± 19.7
APL 30 mg, APOKYN 5 mg and APO-go 5 mg1.21 ± 20.50.89 ± 18.70.75 ± 35.5
Statistical analysis
  • APL-130277, Sublingual Thin Film vs Subcutaneous APO-go · Wilcoxon (Mann-Whitney) · p = 0.0313
  • APL-130277, Sublingual Thin Film vs Subcutaneous APOKYN · Wilcoxon (Mann-Whitney) · p = 0.0625
  • Subcutaneous APOKYN vs Subcutaneous APO-go · Wilcoxon (Mann-Whitney) · p = >0.9999
PrimaryTerminal-phase Rate Constant ( λz)

Apparent terminal elimination rate constant, determined by log linear regression of the plasma concentration versus time data that was judged to be in the log-linear elimination phase. At least 3 data points in the terminal phase will be used in the determination of the rate constant.

Time frame:
Day 1
Reported as:
Geometric mean · /h
Terminal-phase Rate Constant ( λz)
/hAPL-130277, Sublingual Thin FilmSubcutaneous APOKYNSubcutaneous APO-go
APL 20 mg, APOKYN 3 mg and APO-go 3 mg0.62 ± 15.60.71 ± 9.90.80 ± 12.6
APL 25 mg, APOKYN 4 mg and APO-go 4 mg0.63 ± 34.30.59 ± 20.60.68 ± 19.7
APL 30 mg, APOKYN 5 mg and APO-go 5 mg0.57 ± 20.50.78 ± 18.70.92 ± 35.5
PrimaryMetabolite/Parent (M/P) Drug Concentration Ratio -AUC Last

Metabolite (apomorphine sulfate) to Parent exposure ratio, AUClast, corrected for molecular weight differences.

Time frame:
Day 1
Reported as:
Geometric mean · no unit
Metabolite/Parent (M/P) Drug Concentration Ratio -AUC Last
no unitAPL-130277, Sublingual Thin FilmSubcutaneous APOKYNSubcutaneous APO-go
APL 20 mg, APOKYN 3 mg and APO-go 3 mg98.16 ± 6.436.22 ± 3.032.19 ± 9.9
APL 25 mg, APOKYN 4 mg and APO-go 4 mg45.79 ± 169.918.70 ± 162.816.27 ± 221.6
APL 30 mg, APOKYN 5 mg and APO-go 5 mg98.07 ± 55.433.63 ± 6.226.22 ± 43.6

Adverse events

Collected over 16 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
APL-130277, Sublingual Thin Film0/8 (0%)1/8 (12.5%)1/8 (12.5%)
Subcutaneous APOKYN0/7 (0%)0/7 (0%)1/7 (14.3%)
Subcutaneous APO-go0/8 (0%)0/8 (0%)3/8 (37.5%)
Most frequent serious events
Most frequent serious events
EventAPL-130277, Sublingual Thin FilmSubcutaneous APOKYNSubcutaneous APO-go
FallInjury, poisoning and procedural complications1/80/70/8
Rib fractureInjury, poisoning and procedural complications1/80/70/8
Splenic ruptureInjury, poisoning and procedural complications1/80/70/8
Most frequent other events
Most frequent other events
EventAPL-130277, Sublingual Thin FilmSubcutaneous APOKYNSubcutaneous APO-go
NauseaGastrointestinal disorders1/81/72/8
SomnolenceNervous system disorders0/81/70/8
Injection site bruisingGeneral disorders0/80/71/8
DyskinesiaNervous system disorders0/80/71/8
HyperhidrosisSkin and subcutaneous tissue disorders0/80/71/8

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)APL-130277, Then APOKYN, Then APO-goAPL-130277, Then APO-go, Then APOKYNAPOKYN, Then APL-130277, Then APO-goAPOKYN, Then APO-go, Then APL-130277APO-go, Then APL-130277, Then APOKYNAPO-go, Then APOKYN, Then APL-130277Total
<=18 years0000000
Between 18 and 65 years0110013
>=65 years1011115
Age, Continuous
Age, Continuous(Years)APL-130277, Then APOKYN, Then APO-goAPL-130277, Then APO-go, Then APOKYNAPOKYN, Then APL-130277, Then APO-goAPOKYN, Then APO-go, Then APL-130277APO-go, Then APL-130277, Then APOKYNAPO-go, Then APOKYN, Then APL-130277Total
Mean755167.5 ± 9.19677368.5 ± 9.1967.3 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)APL-130277, Then APOKYN, Then APO-goAPL-130277, Then APO-go, Then APOKYNAPOKYN, Then APL-130277, Then APO-goAPOKYN, Then APO-go, Then APL-130277APO-go, Then APL-130277, Then APOKYNAPO-go, Then APOKYN, Then APL-130277Total
Female0100012
Male1021116
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)APL-130277, Then APOKYN, Then APO-goAPL-130277, Then APO-go, Then APOKYNAPOKYN, Then APL-130277, Then APO-goAPOKYN, Then APO-go, Then APL-130277APO-go, Then APL-130277, Then APOKYNAPO-go, Then APOKYN, Then APL-130277Total
Hispanic or Latino0000000
Not Hispanic or Latino1121128
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)APL-130277, Then APOKYN, Then APO-goAPL-130277, Then APO-go, Then APOKYNAPOKYN, Then APL-130277, Then APO-goAPOKYN, Then APO-go, Then APL-130277APO-go, Then APL-130277, Then APOKYNAPO-go, Then APOKYN, Then APL-130277Total
American Indian or Alaska Native0000000
Asian0000000
Native Hawaiian or Other Pacific Islander0000000
Black or African American0000000
White1121128
More than one race0000000
Unknown or Not Reported0000000
Country
Country(Participants)APL-130277, Then APOKYN, Then APO-goAPL-130277, Then APO-go, Then APOKYNAPOKYN, Then APL-130277, Then APO-goAPOKYN, Then APO-go, Then APL-130277APO-go, Then APL-130277, Then APOKYNAPO-go, Then APOKYN, Then APL-130277Total
United States1121128
Height (cm) at Baseline
Height (cm) at Baseline(cm)APL-130277, Then APOKYN, Then APO-goAPL-130277, Then APO-go, Then APOKYNAPOKYN, Then APL-130277, Then APO-goAPOKYN, Then APO-go, Then APL-130277APO-go, Then APL-130277, Then APOKYNAPO-go, Then APOKYN, Then APL-130277Total
Mean172.7157.5174.95 ± 11.243175.3177.8171.25 ± 19.445171.96 ± 10.545
Body Weight (kg) at Baseline
Body Weight (kg) at Baseline(kg)APL-130277, Then APOKYN, Then APO-goAPL-130277, Then APO-go, Then APOKYNAPOKYN, Then APL-130277, Then APO-goAPOKYN, Then APO-go, Then APL-130277APO-go, Then APL-130277, Then APOKYNAPO-go, Then APOKYN, Then APL-130277Total
Mean86.359.486.7 ± 20.5067384.471.2 ± 25.03277.36 ± 15.895

5 further baseline measures are reported on the registry.

08

Study locations

3 sites
  • Parkinson's Disease and Movement Disorders Center of Boca Raton
    Boca Raton, Florida 33486, United States
  • Parkinson's Disese Treatment Center of SW Florida
    Port Charlotte, Florida 33980, United States
  • QUEST Research Institute
    Farmington Hills, Michigan 48334, United States
09

References and documents

Publications

  • Agbo F, Isaacson SH, Gil R, Chiu YY, Brantley SJ, Bhargava P, Navia B. Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson's Disease and "OFF" Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study. Neurol Ther. 2021 Dec;10(2):693-709. doi: 10.1007/s40120-021-00251-6. Epub 2021 May 15. PubMed 33991326 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Mar 2019, 18 months.

Results were first posted in Aug 2020, 1 year 5 months after primary completion. A results delay was requested in Nov 2019.

Of 97 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's 18 months is close to that.

Counting every sponsor, half of 202 studies reached it within 28 months; a quarter within 16 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2017
First posted
Sep 25, 2017
StartActual
Aug 22, 2017
Primary completionActual
Mar 5, 2019
CompletionActual
Mar 5, 2019
Results delay requested
Nov 21, 2019
Results first posted
Aug 13, 2020
Last update
Aug 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03292016
Responsible party
Sponsor
First posted
Sep 25, 2017
Start date
Aug 22, 2017
Primary completion
Mar 5, 2019
Completion
Mar 5, 2019
Results posted
Aug 13, 2020
Last update
Aug 13, 2020

Study contacts

CNS Mecdical Director
study chair · Sunovion Pharmacetuicals Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apomorphine

Start the discussion